Explore the vast range of titles available.

An auto-generated dataset of Curie and Néel temperatures is presented, containing 56,037 records extracted from 108,181 published scientific articles. Each record contains the extracted chemical entity and associated extracted temperature. The dataset was auto-generated by mining text from the papers using the ‘chemistry-aware’ natural-language-processing toolkit, ChemDataExtractor 2.2.2, in conjunction with the Snowball v2 parser, which has been adapted to extract Curie and Néel temperatures from scientific text. This dataset is the first of its kind to be generated using the Snowball v2 parser, with its evaluation yielding a precision of 72% and a recall of 61%. The public availability of this dataset will aid in the design, prediction and analysis of magnetic materials.

\"From the flickering images of the earliest silent films to today's billion-dollar blockbusters, films have captivated the public's eyes, hearts, and psyches. Reflecting - and often creating - the tenor of their times, they combine layers of symbolic and metaphorical images to make a stronger internal impact on their viewers than the still image or the printed word. The compelling pages of Film, Television and the Psychology of the Social Dream illuminate the profound emotional processes involved as films inform and transform our unconscious and conscious minds. Drawing on original and classic scholarship in its field, this provocative volume analyzes these interactions through a wide array of influential films, including pioneering German expressionist works, the Star Trek cycle, and The Godfather. Movies' transformative role in molding philosophies and ethics is shown as the larger meanings of public heroes, stars, fears, and desires evolve, and as salient genres embody more than simply a good story. But despite this century of evolution, the authors assert, one thing remains constant: the critical place of film in communicating individual dreams as well as the shared dreams of a society\"--Back cover.

Anti-retroviral (ARV) -based microbicides are one of the strategies pursued to prevent HIV-1 transmission. Delivery of ARV drugs to subepithelial CD4+ T cells at concentrations for protection is likely determined by drug transporters expressed in the cervicovaginal epithelium. To define the role of drug transporters in mucosal disposition of topically applied ARV-based microbicides, these must be tested in epithelial cell line-based biopharmaceutical assays factoring the effect of relevant drug transporters. We have characterised gene expression of influx and efflux drug transporters in a panel of cervicovaginal cell lines and compared this to expression in cervicovaginal tissue. We also investigated the effect of dapivirine, darunavir and tenofovir, currently at advanced stages of microbicides development, on expression of drug transporters in cell lines. Expression of efflux ABC transporters in cervical tissue was best represented in HeLa, Ect1/E6E7 and End1/E6E7 cell lines. Expression of influx OCT and ENT transporters in ectocervix matched expression in Hela while expression of influx SLCO transporters in vagina was best reflected in VK2/E6E7 cell line. Stimulation with darunavir and dapivirine upregulated MRP transporters, including MRP5 involved in transport of tenofovir. Dapivirine also significantly downregulated tenofovir substrate MRP4 in cervical cell lines. Treatment with darunavir and dapivirine showed no significant effect on expression of BCRP, MRP2 and P-glycoprotein implicated in efflux of different ARV drugs. Darunavir strongly induced expression in most cell lines of CNT3 involved in cell uptake of nucleotide/nucleoside analogue reverse transcriptase inhibitors and SLCO drug transporters involved in cell uptake of protease inhibitors. This study provides insight into the suitability of cervicovaginal cell lines for assessment of ARV drugs in transport kinetics studies. The modulatory effect of darunavir and dapivirine on expression of drug transporters involved in transport of tenofovir points to the possibility of combining these drugs to improve retention of individual drugs at target tissues.

Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of recurrence. We report results from the preplanned interim analysis. We did a multicentre, open-label, randomised controlled phase 3 trial at 48 centres in the UK between July 18, 2007, and March 29, 2012. Patients aged 16 years or older with American Joint Committee on Cancer stage (AJCC) stage IIB, IIC, and III cutaneous melanoma were randomly allocated (1:1), via a central, computer-based minimisation procedure, to receive intravenous bevacizumab 7·5 mg/kg, every 3 weeks for 1 year, or to observation. Randomisation was stratified by Breslow thickness of the primary tumour, N stage according to AJCC staging criteria, ulceration of the primary tumour, and patient sex. The primary endpoint was overall survival; secondary endpoints included disease-free interval, distant-metastases interval and quality of life. Analysis was by intention-to-treat. This trial is registered as an International Standardised Randomised Controlled Trial, number ISRCTN81261306. 1343 patients were randomised to either the bevacizumab group (n=671) or the observation group (n=672). Median follow-up was 25 months (IQR 16–37) in the bevacizumab group and 25 months (17–37) in the observation group. At the time of interim analysis, 286 (21%) of 1343 enrolled patients had died: 140 (21%) of 671 patients in the bevacizumab group, and 146 (22%) of 672 patients in the observation group. 134 (96%) of patients in the bevacizumab group died because of melanoma versus 139 (95%) in the observation group. We noted no significant difference in overall survival between treatment groups (hazard ratio [HR] 0·97, 95% CI 0·78–1·22; p=0·76); this finding persisted after adjustment for stratification variables (HR 1·03; 95% CI 0·81–1·29; p=0·83). Median duration of treatment with bevacizumab was 51 weeks (IQR 21–52) and dose intensity was 86% (41–96), showing good tolerability. 180 grade 3 or 4 adverse events were recorded in 101 (15%) of 671 patients in the bevacizumab group, and 36 (5%) of 672 patients in the observation group. Bevacizumab resulted in a higher incidence of grade 3 hypertension than did observation (41 [6%] vs one [<1%]). There was an improvement in disease-free interval for patients in the bevacizumab group compared with those in the observation group (HR 0·83, 95% CI 0·70–0·98, p=0·03), but no significant difference between groups for distant-metastasis-free interval (HR 0·88, 95% CI 0·73–1·06, p=0·18). No significant differences were noted between treatment groups in the standardised area under the curve for any of the quality-of-life scales over 36 months. Three adverse drug reactions were regarded as both serious and unexpected: one patient had optic neuritis after the first bevacizumab infusion, a second patient had persistent erectile dysfunction, and a third patient died of a haemopericardium after receiving two bevacizumab infusions and was later identified to have had significant predisposing cardiovascular risk factors. Bevacizumab has promising tolerability. Longer follow-up is needed to identify an effect on the primary endpoint of overall survival at 5 years. Cancer Research UK.

Background: Taste loss is a significant problem in older adults, affecting quality of life and nutrition. Altered salivary rheology and loss of mucin function may contribute to taste loss by reducing mucosal defences in the oral cavity, impairing sensitivity to oral stimulants. This study aimed to investigate the effects of salivary rheology on taste loss in ageing. Salivary mucin glycosylation and binding to the oral epithelium was investigated in older and younger adults. A cell-based model was utilised to consider the role of saliva in taste loss. Methods: Human subjects aged >60 years (n = 25) and 18–30 (n = 30) provided saliva samples which were analysed for viscosity, mucin composition and mucin binding to oral epithelial cells (TR146/MUC1). Oral epithelial cells (TR146/MUC1 and SCC090) provided models for taste receptor activation. Results: Reduced levels and sialylation of MUC7 were evident in saliva of older adults which may lead to reduced viscoelasticity, while viscosity is unaffected. Impaired muco-adhesion of saliva from older adults was also observed. Saliva from older adults facilitated the bitter taste receptor activation less well than saliva from younger adults. The causes of taste dysfunction in older adults are unknown, but this study supports a role of saliva in facilitating the activation of taste receptors.

كثيرا ما سأل بيتر إف. دراكر الأشخاص الذين عمل معهم سؤالا بسيطا : كيف تريدون أن يتذكركم الناس ؟. وفي معهد فرانسيس هيسبين للقيادة، وافقنا بالإجماع على مدى أهمية أن نلعب دورا في إلهام الجيل التالي من القادة. وفي عام 2009، اشترك معهد هيسبين مع جامعة بيتسبرج في إطلاق مشروع أكاديمية هيسبين العالمية للقيادة الطلابية والمشاركة المدنية، الذي استقطب 300 طالب موهوب من جميع القارات وعرض عليهم أعمال بيتر دراكر وفرانسيس هيسبين. إن الجيل الأصغر سنا في يومنا هذا-المعروف بجيل الألفية أو الجيل واي، المولود في الفترة ما بين عامي 1980 و 2000-ليس هو الجيل الأكبر بعد، ولكنه أكثر الأجيال تعلما وتنوعا ؛ فقد ضخم حجم التكنولوجيا وسهولة السفر حول العالم من أحلامهم بالعديد من الطرق. وجعلتهم حركة شبكات التواصل الاجتماعي والإعلام الرقمي، بدءا من القنوات المشفرة التقليدية ووصولا إلى مواقع ألفيس بوك وتويتر متواصلين مع بقية العالم بحيث يمكنهم ارتداء الماركات العالمية وكذلك التفاعل مع القضايا حول العالم بطرق استباقية جديدة. كما طوروا شبكات أصدقاء لم تتضمن الجيران أو رفقاءهم في صفوف الرياضة فقط بل تضمنت أصدقاء من أماكن نائية من العالم. ربما لم يلتقوا بهؤلاء الأصدقاء من قبل وجها لوجه، ولكن التواصل فيما بينهم كان له تأثير كبير على حيواتهم، كما نمى لديهم شعورا بالتعاطف العالمي، ولهذا أنا غالبا ما أشير إلى جيل الألفية بأنه الجيل العالمي الأول.

NASA’s Psyche spacecraft launched on October 13, 2023, and soon afterward the mission operations team began spacecraft initial checkout activities. For the electric propulsion system, the feed system and thruster gimbals were first prepared and then the rest of the subsystem completed an initial operations test during thruster bakeout. Thrust for each thruster was measured across the full range of operating powers and was in good agreement with pre-flight expectations. A weeklong test of the spacecraft and mission operations plan during thrusting activities was successful, but a thruster burn-in phenomenon was observed during full power operation that was longer than expected based on previous flight history. Data accumulated during the initial checkout activities shows that this burn-in behavior is different for each thruster and suggests that it is a result of the thruster discharge transitioning between two different plasma modes that can be mitigated by reducing discharge power and by adjusting the thruster magnet current. At the conclusion of the checkout activities, the subsystem had accumulated 357 h of thrusting operations while consuming 18.5 kg of propellant and was fully ready to begin the cruise phase of the mission.